GLYC insider filings
GLYCOMIMETICS INC — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-08-09. Screen GLYC transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for GLYC between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — GLYCOMIMETICS INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-08-09 | 4 | Invus Public Equities, L.P. — 10% owner Invus Public Equities Advisors, LLC — 10% owner Siren, L.L.C. — 10% owner Invus Global Management, LLC — 10% owner DEBBANE RAYMOND — 10% owner | Sale (S): 61,488 @ $0.18 · Sale (S): 260,873 @ $0.19 | EDGAR |
| 2024-08-07 | 4 | Invus Public Equities, L.P. — 10% owner Invus Public Equities Advisors, LLC — 10% owner Siren, L.L.C. — 10% owner Invus Global Management, LLC — 10% owner DEBBANE RAYMOND — 10% owner | Sale (S): 164,523 @ $0.19 · Sale (S): 55,732 @ $0.18 | EDGAR |
| 2024-08-05 | 4 | Invus Public Equities, L.P. — 10% owner Invus Public Equities Advisors, LLC — 10% owner Siren, L.L.C. — 10% owner Invus Global Management, LLC — 10% owner DEBBANE RAYMOND — 10% owner | Sale (S): 63,564 @ $0.22 · Sale (S): 286,200 @ $0.20 | EDGAR |
| 2024-07-30 | 4 | Invus Public Equities, L.P. — 10% owner Invus Public Equities Advisors, LLC — 10% owner Siren, L.L.C. — 10% owner Invus Global Management, LLC — 10% owner DEBBANE RAYMOND — 10% owner | Sale (S): 258,335 @ $0.24 · Sale (S): 363,949 @ $0.24 · Sale (S): 756,835 @ $0.22 | EDGAR |
| 2024-06-24 | 4 | Rock Edwin — Chief Medical Officer | Purchase (P): 190,000 @ $0.25 · Purchase (P): 115,000 @ $0.27 | EDGAR |
| 2024-06-20 | 4 | Hahn Brian M. — SVP Finance, CFO | Purchase (P): 17,500 @ $0.25 | EDGAR |
| 2024-05-01 | 4 | Koenig Scott — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-05-01 | 4 | Goldberg Mark Alan — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-05-01 | 4 | PEARSON TIMOTHY R — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-05-01 | 4 | King Rachel K. — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-05-01 | 4 | Andrews Patricia S — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-05-01 | 4 | Jackson Scott Thomas — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-05-01 | 4 | JUNIUS DANIEL M — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | Goldberg Mark Alan — Director | Grant/award (A): 4,584 @ $3 | EDGAR |
| 2024-04-02 | 4 | King Rachel K. — Director | Grant/award (A): 3,334 @ $3 | EDGAR |
| 2024-04-02 | 4 | JUNIUS DANIEL M — Director | Grant/award (A): 5,209 @ $3 | EDGAR |
| 2024-01-17 | 4 | Johnson Bruce S — SVP & Chief Commercial Officer | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Semerjian Harout — Chief Executive Officer, Director | Grant/award (A): 695,000 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Rock Edwin — Chief Medical Officer | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Rath Chinmaya — SVP and Chief Business Officer | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Hahn Brian M. — SVP Finance, CFO | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2024-01-02 | 4 | Andrews Patricia S — Director | Grant/award (A): 5,191 @ $2.36 | EDGAR |
| 2024-01-02 | 4 | King Rachel K. — Director | Grant/award (A): 4,238 @ $2.36 | EDGAR |
| 2024-01-02 | 4 | Goldberg Mark Alan — Director | Grant/award (A): 5,827 @ $2.36 | EDGAR |
| 2023-10-03 | 4 | Goldberg Mark Alan — Director | Grant/award (A): 9,167 @ $1.50 | EDGAR |
| 2023-10-03 | 4 | Andrews Patricia S — Director | Grant/award (A): 8,167 @ $1.50 | EDGAR |
| 2023-10-03 | 4 | King Rachel K. — Director | Grant/award (A): 6,667 @ $1.50 | EDGAR |
| 2023-09-25 | 4 | Rock Edwin — Chief Medical Officer | Purchase (P): 35,000 @ $1.38 · Purchase (P): 30,403 @ $1.38 | EDGAR |
| 2023-06-02 | 4 | Koenig Scott — Director | Option exercise (M): 21,000 @ $0.60 · Option exercise (M): 21,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | King Rachel K. — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | Koenig Scott — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | Goldberg Mark Alan — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | PEARSON TIMOTHY R — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | Andrews Patricia S — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | Jackson Scott Thomas — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | JUNIUS DANIEL M — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2023-05-18 | 4 | Hahn Brian M. — SVP Finance, CFO | Sale (S): 3,700 @ $1.95 | EDGAR |
| 2023-05-11 | 4 | JUNIUS DANIEL M — Director | Purchase (P): 30,000 @ $1.56 | EDGAR |
| 2023-05-09 | 4 | Johnson Bruce S — SVP & Chief Commercial Officer | Purchase (P): 13,500 @ $1.57 | EDGAR |
| 2023-02-28 | 4 | Invus Public Equities, L.P. — 10% owner Artal International S.C.A. — 10% owner Artal International Management S.A. — 10% owner Artal Group S.A. — 10% owner Westend S.A. — 10% owner Wittouck Amaury — 10% owner Stichting Administratiekantoor Westend — 10% owner Invus Public Equities Advisors, LLC — 10% owner | Purchase (P): 100,000 @ $1.70 | EDGAR |
| 2023-02-23 | 4 | Invus Public Equities, L.P. — 10% owner Artal International S.C.A. — 10% owner Artal International Management S.A. — 10% owner Artal Group S.A. — 10% owner Westend S.A. — 10% owner Wittouck Amaury — 10% owner Stichting Administratiekantoor Westend — 10% owner Invus Public Equities Advisors, LLC — 10% owner | Purchase (P): 50,000 @ $1.85 · Purchase (P): 150,000 @ $1.79 · Purchase (P): 200,000 @ $1.75 | EDGAR |
| 2023-02-17 | 4 | Invus Public Equities, L.P. — 10% owner Artal International S.C.A. — 10% owner Artal International Management S.A. — 10% owner Artal Group S.A. — 10% owner Westend S.A. — 10% owner Wittouck Amaury — 10% owner Stichting Administratiekantoor Westend — 10% owner Invus Public Equities Advisors, LLC — 10% owner | Purchase (P): 1,000,000 @ $2.16 · Purchase (P): 315,266 @ $1.68 · Purchase (P): 200,000 @ $1.71 | EDGAR |
| 2023-02-13 | 4 | Invus Public Equities, L.P. — 10% owner Artal International S.C.A. — 10% owner Artal International Management S.A. — 10% owner Artal Group S.A. — 10% owner Westend S.A. — 10% owner Wittouck Amaury — 10% owner Stichting Administratiekantoor Westend — 10% owner Invus Public Equities Advisors, LLC — 10% owner | Purchase (P): 11,451 @ $3.24 | EDGAR |
| 2023-01-30 | 4 | Koenig Scott — Director | Option exercise (M): 10,500 @ $2.55 · Option exercise (M): 10,500 (derivative) @ $0 | EDGAR |
| 2023-01-27 | 4 | SANDELL SCOTT D — 10% owner | Sale (S): 358,371 @ $3.26 · Sale (S): 293,645 @ $3.26 · Sale (S): 1,648,908 @ $3.12 · Sale (S): 1,351,092 @ $3.12 | EDGAR |
| 2023-01-20 | 4 | Hahn Brian M. — SVP Finance, CFO | Grant/award (A): 246,300 (derivative) @ $0 | EDGAR |
| 2023-01-20 | 4 | Semerjian Harout — Chief Executive Officer, Director | Grant/award (A): 651,200 (derivative) @ $0 | EDGAR |
| 2023-01-20 | 4 | Rock Edwin — Chief Medical Officer | Grant/award (A): 244,800 (derivative) @ $0 | EDGAR |
| 2023-01-06 | 4 | SANDELL SCOTT D — 10% owner | Sale (S): 39,223 @ $2.76 · Sale (S): 32,139 @ $2.76 | EDGAR |
| 2023-01-04 | 4 | SANDELL SCOTT D — 10% owner | Sale (S): 66,690 @ $3.02 · Sale (S): 54,645 @ $3.02 · Sale (S): 96,084 @ $2.99 · Sale (S): 78,730 @ $2.99 · Sale (S): 56,054 @ $2.91 · Sale (S): 45,930 @ $2.91 | EDGAR |
Recent 8-K events — GLYCOMIMETICS INC
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-15 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-07-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-14 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-06-03 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-04-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=GLYC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs